They have expanded from 130 beds in FY23 to 330 beds towards the end of H1 FY24 and are planning to increase capacity to 430 by FY25.
They had 23.74 Cr revenue in FY23 so that increase in capacity should boost revenues. Would have been better to see the revenue contribution in Q3 from the capex.
Also, the 2 IVF centres that they’re planning to acquire and invest 4-5 Cr in. Since, the MD is a gynecologist himself, this should have good synergy.
Then again, management is very bullish but the stock is trending in opposite direction. I am also looking to build my conviction.
| Subscribe To Our Free Newsletter |
